223 related articles for article (PubMed ID: 35302839)
1. Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy.
Cao X; Chen J; Li B; Dang J; Zhang W; Zhong X; Wang C; Raoof M; Sun Z; Yu J; Fakih MG; Feng M
Sci Adv; 2022 Mar; 8(11):eabl9171. PubMed ID: 35302839
[TBL] [Abstract][Full Text] [Related]
2. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
Watanabe M; Wallace PK; Keler T; Deo YM; Akewanlop C; Hayes DF
Breast Cancer Res Treat; 1999 Feb; 53(3):199-207. PubMed ID: 10369066
[TBL] [Abstract][Full Text] [Related]
3. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis.
Naicker SD; Feerick CL; Lynch K; Swan D; McEllistrim C; Henderson R; Leonard NA; Treacy O; Natoni A; Rigalou A; Cabral J; Chiu C; Sasser K; Ritter T; O'Dwyer M; Ryan AE
Oncoimmunology; 2021 Jan; 10(1):1859263. PubMed ID: 33552684
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages.
Su S; Zhao J; Xing Y; Zhang X; Liu J; Ouyang Q; Chen J; Su F; Liu Q; Song E
Cell; 2018 Oct; 175(2):442-457.e23. PubMed ID: 30290143
[TBL] [Abstract][Full Text] [Related]
6. Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies.
VanDerMeid KR; Elliott MR; Baran AM; Barr PM; Chu CC; Zent CS
Cancer Immunol Res; 2018 Oct; 6(10):1150-1160. PubMed ID: 30089638
[TBL] [Abstract][Full Text] [Related]
7. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
8. A real-time antibody-dependent cellular phagocytosis assay by live cell imaging.
Shi Y; Sun Y; Seki A; Rutz S; Koerber JT; Wang J
J Immunol Methods; 2024 Jun; 531():113715. PubMed ID: 38936465
[TBL] [Abstract][Full Text] [Related]
9. Macrophage N-glycan processing inhibits antibody-dependent cellular phagocytosis.
Díaz de León JSA; Aguilar I; Barb AW
Glycobiology; 2023 Dec; 33(12):1182-1192. PubMed ID: 37792857
[TBL] [Abstract][Full Text] [Related]
10. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
Upton R; Banuelos A; Feng D; Biswas T; Kao K; McKenna K; Willingham S; Ho PY; Rosental B; Tal MC; Raveh T; Volkmer JP; Pegram MD; Weissman IL
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34257155
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages.
Shi Y; Fan X; Deng H; Brezski RJ; Rycyzyn M; Jordan RE; Strohl WR; Zou Q; Zhang N; An Z
J Immunol; 2015 May; 194(9):4379-86. PubMed ID: 25795760
[TBL] [Abstract][Full Text] [Related]
12. Macrophage hypophagia as a mechanism of innate immune exhaustion in mAb-induced cell clearance.
Pinney JJ; Rivera-Escalera F; Chu CC; Whitehead HE; VanDerMeid KR; Nelson AM; Barbeau MC; Zent CS; Elliott MR
Blood; 2020 Oct; 136(18):2065-2079. PubMed ID: 32556153
[TBL] [Abstract][Full Text] [Related]
13. Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages.
Zeller T; Lutz S; Münnich IA; Windisch R; Hilger P; Herold T; Tahiri N; Banck JC; Weigert O; Moosmann A; von Bergwelt-Baildon M; Flamann C; Bruns H; Wichmann C; Baumann N; Valerius T; Schewe DM; Peipp M; Rösner T; Humpe A; Kellner C
Front Immunol; 2022; 13():929339. PubMed ID: 36389667
[TBL] [Abstract][Full Text] [Related]
14. Protocol for the murine antibody-dependent cellular phagocytosis assay.
Stanganello E; Brkic M; Zenner S; Beulshausen I; Schmitt U; Vascotto F
Methods Cell Biol; 2023; 173():109-120. PubMed ID: 36653078
[TBL] [Abstract][Full Text] [Related]
15. Anticancer efficacy of monotherapy with antibodies to SIRPα/SIRPβ1 mediated by induction of antitumorigenic macrophages.
Sakamoto M; Murata Y; Tanaka D; Kakuchi Y; Okamoto T; Hazama D; Saito Y; Kotani T; Ohnishi H; Miyasaka M; Fujisawa M; Matozaki T
Proc Natl Acad Sci U S A; 2022 Jan; 119(1):. PubMed ID: 34949714
[TBL] [Abstract][Full Text] [Related]
16. A novel method for determining antibody-dependent cellular phagocytosis.
Kamen L; Myneni S; Langsdorf C; Kho E; Ordonia B; Thakurta T; Zheng K; Song A; Chung S
J Immunol Methods; 2019 May; 468():55-60. PubMed ID: 30880262
[TBL] [Abstract][Full Text] [Related]
17. Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis.
Kamber RA; Nishiga Y; Morton B; Banuelos AM; Barkal AA; Vences-Catalán F; Gu M; Fernandez D; Seoane JA; Yao D; Liu K; Lin S; Spees K; Curtis C; Jerby-Arnon L; Weissman IL; Sage J; Bassik MC
Nature; 2021 Sep; 597(7877):549-554. PubMed ID: 34497417
[TBL] [Abstract][Full Text] [Related]
18. Macrophages are critical effectors of antibody therapies for cancer.
Weiskopf K; Weissman IL
MAbs; 2015; 7(2):303-10. PubMed ID: 25667985
[TBL] [Abstract][Full Text] [Related]
19. Enhancing antibody-dependent cellular phagocytosis by Re-education of tumor-associated macrophages with resiquimod-encapsulated liposomes.
Li H; Somiya M; Kuroda S
Biomaterials; 2021 Jan; 268():120601. PubMed ID: 33338932
[TBL] [Abstract][Full Text] [Related]
20. Differential influence on antibody dependent cellular phagocytosis by different glycoforms on therapeutic Monoclonal antibodies.
Kuhns S; Shu J; Xiang C; Guzman R; Zhang Q; Bretzlaff W; Miscalichi N; Kalenian K; Joubert M
J Biotechnol; 2020 Jun; 317():5-15. PubMed ID: 32361021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
